AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03495609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovitrelle
Description: Ovitrelle will be injected in 35 asymptomatic women with BRCA1 or BRCA2 mutation during 90 days (an extra 4 weeks in a subgroup). The gene expression of the breast epithelial cells will be characterized and compared to the gene expression of the breast epithelial cells before ovitrelle injection.
Study NCT04156542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic School Lunchroom Nudges
Description: The intervention consists of three components: 1) serving fresh fruit in attractive bowls in at least two locations on the lunch line; 2) providing descriptive names for the vegetables; and 3) increasing amount of plain milk availability by 10% and placing it in front of the chocolate milk. For the vegetable naming intervention, researchers first developed, printed, and laminated descriptive vegetable name cards (2x4). Some examples included Savory Collard Greens, and \[School Mascot\] Salad. Cafeteria staff affixed name cards to the serving line sneeze-guards in front of the vegetables for the day. For the fruit intervention, we purchased and delivered two ceramic bowls to the intervention school. The cafeteria staff filled the bowls and put them in different locations on the lunch line. For the milk intervention, cafeteria staff increased the amount of plain milk available by 10% and placed plain in front of chocolate milk in the coolers.
Study NCT00220779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Study NCT00761020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: To determine the seroconversion rate (sensitivity) to Plasmodium falciparum Merozoite Surface Protein 1 (Pf MSP-1) antigen by ELISA assay in the infectivity control and mefloquine cohorts as part of a larger project to support the qualification of anti-MSP-1 antigen-specific antibody assays as valid surrogate endpoints for malaria infection.
Study NCT00761020 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No Intervention
Study NCT00220779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin (Human) 25%, United States Pharmacopeia (USP)
Study NCT03561532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: FMT administered into the cecum of the patient in colonoscopy.
Study NCT03561532 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Autologous FMT (fecal suspension made of patients own feces) administered into the cecum of the patient in colonoscopy.
Study NCT00639743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo ( group B)
Description: placebo ( group B)
Study NCT00639743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenecteplase (group A)
Description: tenecteplase (group A)
Study NCT00904410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: 370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
Study NCT02935829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Ten subjects (male: 6, female: 4) consumed 25g glucose diluted in 250ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT02935829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread as reference food
Description: Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from white bread along with 250ml water, two times, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT02935829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carob snack as test food
Description: Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from carob snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT02935829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate cookie snack as test food
Description: Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from chocolate cookie snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT02935829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carob preload
Description: Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g carob snack). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
Study NCT02935829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate cookie preload
Description: Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g chocolate cookie). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
Study NCT04642001 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Photon Laser III-DMC (without radiation emission) + My First- Colgate
Description: Positioning of the FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
Study NCT04642001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photon Laser III-DMC (without radiation emission) + Sensodyne® Rapid Relief / GSK
Description: Positioning of FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
Study NCT04642001 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Laser III-DMC (with irradiation emission) + My First- Colgate
Description: Emission of FBM therapy (Photon Laser III / DMC), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
Study NCT04642001 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photon Laser III-DMC (with irradiation emission) +Sensodyne® Rapid Relief / GSK
Description: Emission of FBM therapy (Photon Laser III / DMC), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
Study NCT02226679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algisyl-LVR
Description: Algisyl-LVR™ device (implants) administered during a surgical procedure
Study NCT00476671 — intervention group
Intervention type: PROCEDURE
Intervention: lumbar puncture, MRI, MRS
Description: lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia
Study NCT00813943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide (2-times weekly)
Description: Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
Study NCT00813943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide (5-times weekly)
Description: Cilengitide 2000 milligram (mg) will be administered intravenously 5-times weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
Study NCT02404662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive text messages intervention
Description: The supportive text messages are based on existing aphorisms in the recovery literature. Each day patients will receive one message targeting mood and another message targeting abstinence from alcohol in accordance with the primary aims of our study. An example text message aimed at improving mood is: Monitor changes in your mood; develop a list of personal warning signs. An example message targeting abstinence is: Keep Sobriety as a number one priority and you will reach your goals. None of the messages will be repeated. The messages will be sent in the morning and evening, with the theme (mood/alcohol) of the messages pseudo-randomised according to delivery time, so that no more than three successive days will have the same theme sent at the same time slot.
Study NCT02404662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will receive treatment as usual, as well as fortnightly thank you text messages and calls to ensure that they are still using their phone.
Study NCT03717350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously administered once
Study NCT00813943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
Study NCT00813943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
Study NCT00813943 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.
Study NCT00813943 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.
Study NCT01209104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: 100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
Study NCT01008241 — intervention group
Intervention type: BEHAVIORAL
Intervention: Paper questionnaire
Description: Participants will complete a paper and pencil questionnaire that measures 4 domains of interest (advanced care planning; end of life care; hospice care and death and dying) as well as demographic factors (age, marital status, education etc.)
Study NCT01410357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Training in Illness Management (TTIM)
Description: This intervention blends psychoeducation, problem identification/goal-setting, behavioral modeling and reinforcement via use of Peer Educators, and health care linkage, has been adapted to the primary care setting and targeted for SMI-DM participants. Generalizability is enhanced with relatively brief in-person participation requirements and by utilizing professional staff typically found in primary care. TTIM will stress information sharing that is accessible to participants, and through a collaborative process, foster motivation for SMI-DM self-management.
Study NCT02845219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once daily alone or together with oral contraceptive.
Study NCT02845219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNAC
Description: Oral administration once daily together with oral contraceptive.
Study NCT02845219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Description: Oral administration once daily alone or together with oral semaglutide or SNAC.
Study NCT03560700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactobacillus probiotic strain
Description: Approved Dietary supplement
Study NCT03560700 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study NCT02775019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: 2 x daily repeated consumption of a lozenge containing 10E9 CFU Lactobacillus reuteri for 42 days
Study NCT01505894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study NCT03480802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
Study NCT03480802 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
Study NCT03480802 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
Study NCT03480802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
Study NCT01703000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (NG PROMUS)
Description: Interventional coronary artery stenting with NG PROMUS study stent.
Study NCT00289913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: VAQTA™
Description: VAQTA™ (Hepatitis A Vaccine, Inactivated).~Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age.
Study NCT00289913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Infanrix™
Description: Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis~Vaccine Adsorbed, GlaxoSmithKline).~One intramuscular 0.5-mL injection of Infanrix™ was administered at the first study visit.
Study NCT02775019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x daily repeated consumption of a lozenge being void of Lactobacillus reuteri for 42 days
Study NCT00288899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced surgical iMedConsent process (with repeat back)
Description: Consent process engages patient in discussion about why they are having procedure, risks, benefits, alternatives. Then provider asks patient to repeat backwhat they understand.
Study NCT00288899 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard surgical iMedConsent process
Description: Patients are consented in standard VA consent process, where are not necessarily asked to repeat back and no discussion is necessarily documented.
Study NCT01198522 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine
Description: Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.~Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29.
Study NCT00205270 — intervention group
Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season
Study NCT01268280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.
Study NCT01268280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.
Study NCT01268280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.
Study NCT04844710 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: acupuncture and standard care
Description: manual acupuncture in acupoint LI4, LI11, ST36 every 2 days for 6 times standard care
Study NCT04844710 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: standard care
Description: standard care only
Study NCT01199367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2450 in combination with lapatinib and letrozole
Description: Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
Study NCT02396160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Urox
Description: Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs
Study NCT02396160 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment
Study NCT02236182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide low dose
Study NCT03717350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100ml of sodium chloride 0.9% within 15 minutes intravenously once
Study NCT02236182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02236182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide high dose
Study NCT00234286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comfort care education intervention
Description: Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
Study NCT01650012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplerenone
Description: target 50 mg per day titrated down for hyperkalemia or hypotension
Study NCT01650012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02085642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Single disposal needle to be used, 0.02 mm x 25 mm in length
Study NCT02085642 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham needle
Description: Retractable needle with no skin puncture
Study NCT03005873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC599 LD group
Description: Single dose via intra-articular injection
Study NCT03005873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single dose via intra-articular injection
Study NCT03005873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC599 HD group
Description: Single dose via intra-articular injection
Study NCT02489929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment for patient suffering of MDS or Myeloid leukemia
Study NCT02489929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine